Cigna Offers Cleaner Growth Than Other Health Insurers, Says Analyst

BofA warns that managed-care stocks face rising cost pressures, unpredictable swing factors and heightened uncertainty around earnings estimates—with Medicare posing greater risk than Medicaid and reported EPS potentially understating underlying earnings power—yet the bank sees meaningful long-term upside as most MCOs are earning below their potential. At the company level BofA favors Cigna for its clean commercial exposure and scaled PBM/specialty-pharmacy franchise that should capture secular drug‑spend tailwinds (obesity therapies, biosimilars, gene/cell therapies); Cigna is modeled for 10–15% annual EPS growth post‑2026, trades at roughly an 8.1x 2027 multiple and ~12% FCF yield, and could re‑rate toward historical 10–12x. BofA is also constructive on Alignment Healthcare (expecting 20%+ member growth and Stars tailwinds) and views UnitedHealth as well‑positioned if the 2027 Medicare Advantage rate proposal (due Feb. 18) signals stability—allowing rolloff of a roughly $6bn V28 headwind and margin expansion in 2027—while Centene and Molina face Medicaid enrollment declines that complicate rate setting and leave exchange pricing and execution unlikely to be rewarded before at least Q2 2026.

Analysis

BofA Securities flags rising cost pressures and unpredictable swing factors across managed-care organizations, noting Medicare risks exceed Medicaid risks and that reported EPS may not fully reflect underlying earnings power. The firm still sees meaningful long-term upside, arguing most MCOs are earning below potential, but assigns a mixed sentiment to the sector and judges near-term visibility as limited (market impact score 0.35).

At the company level BofA prefers Cigna for its concentrated commercial-insurance exposure and scaled PBM/specialty pharmacy platform, forecasting 10%–15% annual EPS growth after a 2026 reset, a roughly 12% free-cash-flow yield and an 8.1x 2027 earnings multiple with re-rating potential to Cigna’s historical 10x–12x. BofA is also constructive on Alignment Healthcare, forecasting 20%+ member growth and Stars-driven tailwinds into 2026.

UnitedHealth’s outlook is contingent on the 2027 Medicare Advantage rate proposal due Feb. 18; stability there would allow the ~$6 billion (≈$5.25 EPS) V28 headwind expected in 2026 to roll off and materially expand margins in 2027. Centene and Molina face ongoing Medicaid enrollment declines that complicate rate-setting and leave exchange-pricing and execution visibility poor until at least Q2 2026.

Key Decisions for Investors

• Consider overweighting Cigna selectively given the 10%–15% post‑2026 EPS growth outlook, ~12% FCF yield and potential re‑rating from 8.1x to 10x–12x if PBM changes reduce regulatory overhang
• Monitor the Feb. 18, 2027 Medicare Advantage rate proposal closely and be prepared to add to UnitedHealth on signs of rate stability that enable roll‑off of the ~$6bn V28 headwind, otherwise maintain caution
• Avoid increasing exposure to Centene and Molina until exchange pricing and Medicaid enrollment trends clarify—expect the market to remain unreceptive to execution until at least Q2 2026 and consider hedges for downside risk
• Allocate a smaller, opportunistic position to Alignment Healthcare to capture expected 20%+ member growth and Stars tailwinds while recognizing limited near‑term visibility and sector cost pressure risks